✨ I’m examining DEB versus DES in coronary bifurcations, focusing on MACE, TLR, restenosis, mortality, and MI. Comparing patient outcomes to identify which groups might benefit more.

🔍 Searched for drug-coated balloon vs stent outcomes

✨ I'm examining meta-analyses and RCTs comparing drug-coated balloons (DCBs) and drug-eluting stents (DES) for treating coronary bifurcations, particularly side branches. This review aims to identify the most effective strategy.

🔍 Searched for DEB vs DES side branch bifurcation trial

✨ I'm exploring strategies like DCB-only or a combo with stents, focusing on their efficacy in coronary bifurcation lesions. Notably, I'm examining long-term outcomes like MACE, TLR, and restenosis.

✨ I’m piecing together the differences between DCB on the side branch, DCB on the main branch, and no stent for less severe cases. Hybrid approaches might combine these strategies.

🔍 Searched for DCB vs DES bifurcation meta analysis 2022

✨ I’m gathering info on systematic reviews and meta-analysis of DCB vs POBA/DES, with a focus on left main and non-aorto ostial coronary lesions. Current references range from AHA journal to JSCAI.

✨ I'm analyzing how systematic reviews and meta analyses inform evidence, especially regarding outcomes that might be influenced by data from observational studies or non-RCTs.

🔍 Searched for DCB vs POBA/DES bifurcation studies

✨ OK, let me see. I’m piecing together references to articles on platforms like ScienceDirect, PLOS ONE, PubMed, and ResearchGate discussing topics such as coronary artery disease treatments and drug-coated balloons.

🌐 Read journals.plos.org

✨ OK, let me see. DCB shows promise in side branches but lacks robust RCTs against current DES. Recent meta-analysis reports DCB's performance in large vessels, potentially redefining its application.

🌐 Read pubmed.ncbi.nlm.nih.gov

✨ I evaluated 13 studies, including RCTs and observational ones. No significant differences were found between DCB and DES in cardiovascular death, MI, TLR, all-cause death, or late lumen loss. More RCTs are needed to verify these findings.

🌐 Read acc.org

✨ Evaluating the DCB-BIF comparative outcomes, including minimization of side branch MI with DCB. Considering DCB for both main and side branches as a sole treatment.

🌐 Read journals.plos.org

✨ I'm reflecting on scrolling a bit more to explore the content thoroughly.

🌐 Read more from journals.plos.org

✨ I’m thinking through DCB and BMS trials, emphasizing lesion type. Results hint at DCB's superiority, despite some limitations.

🌐 Read more from journals.plos.org

✨ Comparing DCB and POBA for bifurcations. Emphasizing DCB's benefits over stenting, especially in proximal outcomes. Progressing to broader trials next.

🔍 Searched for DEBIUT trial drug-coated balloon bifurcation

✨ I’m gathering info on the DEBIUT study, likely comparing a paclitaxel DCB with or without stenting side branches. The BABILON trial seems to involve a provisional T-stenting technique for coronary bifurcations.

🌐 Read pubmed.ncbi.nlm.nih.gov

✨ Noticing that paclitaxel DCB and BMS didn't surpass DES, but recent data suggest DCB is now comparable in certain scenarios.

🔍 Searched for DCB short DAPT bifurcation high bleeding risk study

✨ Considering the impact of short versus long DAPT in high bleeding risk patients and exploring the optimal use of DCB in various scenarios. Progress is being made in understanding these dynamics.

🔍 Searched for coronary bifurcation drug-coated balloon stent prognosis study

✨ I’m seeing a research progress summary on DES combined with DCB for true coronary bifurcation lesions.

🌐 Read hanspub.org

✨ Bifurcation lesions, consisting of both main and side branch narrowing, are challenging and require precise treatment strategies. Using DCB in the side branch can alleviate stent-related problems and reduce late luminal loss.

🌐 Read more from hanspub.org

✨ I’m comparing DCB, plain balloon, and two-stents in true bifurcation side branch. The DCB group shows lower LLL and fewer MACE than plain balloon or two-stents.

🔍 Searched for Shugushev bifurcation DCB side branch

✨ Gathering data to compare outcomes of DCB and DES. Progressing through meta-analyses and RCTs for comprehensive analysis.

🔍 Searched for DCB vs DES effectiveness and safety meta-analysis

✨ OK, I’m seeing that DCB's one-year results in Caminiti's meta suggest no inferiority. The DEBUT trial, from around 2020, compares DCB and DES in high bleeding risk patients.

🔍 Searched for DEBUT trial DCB vs DES high bleeding risk

✨ I'm thinking through the DEBUT trial, comparing DCB with BMS, and noting that DCB might be better for HBR patients. I'm also examining various trial outcomes like MACE and TLR.

🔍 Searched for BABILON trial bifurcation DCB results

✨ Paclitaxel DEB pretreatment with BMS in main branches and plain balloons in side branches shows worse LLL and MACE vs EES.

🌐 Read tctmd.com

✨ I’m noting results from the BABILON trial, showing higher restenosis rates with PEB, contrasting favorably with EES. This suggests that in modern context, EES might still outperform PEB.

🌐 Read hanspub.org

✨ DCB outperforms conventional stenting in small vessels, bifurcations, and ISR, showing fewer adverse events and improved heart function.

🌐 Read pubmed.ncbi.nlm.nih.gov

✨ I’m gathering insights from Jiang & Liu's meta-analysis, noting DCB advantages over plain balloon in provisional DES, and contemplating side branch strategies and outcome comparisons.

✨ OK, let me see. I’m piecing together data from various sources to shed light on the long-term clinical outcomes of DCB-based PCI compared to POBA and DES, focusing on MACE, TLR, restenosis, mortality, and MI.

🌐 Read more from pubmed.ncbi.nlm.nih.gov

✨ OK, let's map out the appropriate citation for the snippet, ensuring clarity and adherence to guidelines.

🌐 Read more from pubmed.ncbi.nlm.nih.gov

✨ I'm considering different study comparisons, focusing on TLR rates for DCB-BIF and DCB vs DES, ensuring clear differentiation and avoiding mixing data sources.

🔍 Searched for BASKET SMALL 2 DCB vs DES MACE TLR results

✨ Reining in the scope to bifurcation lesions, integrating bifurcation-specific studies, and potentially using Chinese sources for brevity benefits.

✨ I’m noting the advantages of DCB for small vessel lesions and bifurcations, with a particular focus on patients with ISR, as suggested by some studies and consensus.

🌐 Read tctmd.com

✨ I’m thinking through the link between bypass graft failure and subsequent patient outcomes, including myocardial infarction, cerebrovascular accident, and death.

🌐 Read more from tctmd.com

✨ OK, let me see. DCB should only be used in patients with ISR, high bleeding risk, or bifurcation. This narrows down the appropriate candidate pool.

🌐 Read journals.plos.org

✨ I'm working through images in PLOS content, aiming to find the key ones at [189], [190], etc., for the table.

✨ I’m thinking Table 1 might provide study details, but it’s not quite what’s needed.

✨ I’m gathering info to decide if action is necessary and weighing options.

✨ I’m gathering data to compare various bifurcation approaches. Progressing from older RCTs to newer outcomes, I’m examining DCB and stent alternatives.

🌐 Read hanspub.org

✨ Mapping out Drug-Coated Balloon (DCB) use for side branches. Considering key factors: high bleeding risk, minimal DAPT, and targeting specific lesion types.

Two-stent strategy's high MACE rates prompt a look at one-stent plus DCB. Prioritizing high bleeding risk and shortened DAPT is essential.

🌐 Read tctmd.com

✨ I’m pulling together MACE, TLR, MI, and mortality outcomes from various studies, including BASKET-SMALL and meta-analyses, to present a clear comparative analysis.

🌐 Read acc.org

✨ I'm examining DCB usage for simple bifurcations, which is aligned with the medical reference.

🌐 Read more from acc.org

✨ I'm gathering info on bifurcation types and considering including a brief mention of left main interest. Let's craft a clear, data-backed response in Chinese.

Research completed in 11m